CSF1R and renal cell carcinoma: Among them, drugs affecting the M-CSF/CSF1R axis and PI3Kγ are being tested in advanced solid tumors, glioblastoma, sarcoma, breast cancer, and renal cell carcinoma [11, 49, 56].